摘要
Abstract
Objective:To study the effect of Sacubitril and Valsartan combined with Metoprolol in the treatment of patients with chronic heart failure(CHF).Method:A total of 94 CHF patients admitted to the Chongqing Wansheng Economic and Technological Development Zone Traditional Chinese Medicine Hospital from January 2022 to September 2023 were selected.According to random number table method,the patients were divided into study group and control group,47 cases in each group.The control group was given Metoprolol,and the study group was given Metoprolol combined with Sacubitril and Valsartan.The serological indexes,cardiac function indexes,inflammatory factors,vascular endothelial function indexes before and after treatment and adverse reactions were compared between the two groups.Result:After treatment,the amino terminal brain natriuretic peptide precursor(NT-proBNP),intercellular adhesion molecule-1(ICAM-1),angiotensin Ⅱ(AngⅡ),growth differentiation factor 15(GDF-15),soluble growth stimulation expression gene 2 protein(sST2),human cyclophilin(CypA),interleukin-6(IL-6),high sensitive C-reactive protein(hs-CRP)and procalcitonin(PCT)levels in the study were lower than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the left ventricular short axis shortening rate(LVFS),left ventricular ejection fraction(LVEF),output per bo(SV),nitric oxide(NO),calcitonin gene-related peptide(CGRP)and nitric oxide synthase(NOS)in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Sacubitril and Valsartan combined with Metoprolol can effectively improve the serological indexes,cardiac function and vascular endothelial function of CHF patients,and reduce the level of inflammatory factors.关键词
慢性心力衰竭/沙库巴曲缬沙坦/美托洛尔/心功能Key words
Chronic heart failure/Sacubitril and valsartan/Metoprolol/Cardiac function
